Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is facing long-term challenges in their competitive commercial and clinical development landscapes, which could impact the visibility and growth potential of their key drug, Cabometyx. However, they have a strong balance sheet and sustainable profitability compared to their mid-cap peers, making them an attractive investment opportunity for the future if they are able to execute on their pipeline and business development plans. A potential opportunity to invest in Exelixis may arise if a more attractive entry point becomes available.

Bears say

Exelixis is facing several challenges that impact its outlook, including generic erosion of its existing franchises, potential safety and tolerability concerns with its independent solution to Cabometyx, zanzalintinib, and possible long-term dilution risk. Additionally, the company's upcoming PDUFA date for its potential approval for zanzalintinib in 3L MSS mCRC, as well as data disclosures and trial initiations related to the drug, will be important factors for investors to watch. However, the company's expansion of its sales force and efforts to accelerate Cabometyx utilization may provide some support for its stock, though our negative outlook remains largely unchanged.

Exelixis (EXEL) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 16 analysts, Exelixis (EXEL) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.